Boston Trust Walden Corp Sells 684 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Boston Trust Walden Corp lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 14,677 shares of the medical equipment provider’s stock after selling 684 shares during the period. Boston Trust Walden Corp’s holdings in Intuitive Surgical were worth $7,661,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Czech National Bank grew its position in Intuitive Surgical by 6.9% in the 3rd quarter. Czech National Bank now owns 72,257 shares of the medical equipment provider’s stock worth $35,498,000 after purchasing an additional 4,665 shares during the period. GAMMA Investing LLC boosted its position in shares of Intuitive Surgical by 31.2% in the third quarter. GAMMA Investing LLC now owns 5,090 shares of the medical equipment provider’s stock worth $2,501,000 after purchasing an additional 1,211 shares during the period. Consilio Wealth Advisors LLC purchased a new stake in Intuitive Surgical in the 3rd quarter worth $218,000. Miracle Mile Advisors LLC raised its stake in Intuitive Surgical by 7.7% during the 3rd quarter. Miracle Mile Advisors LLC now owns 1,805 shares of the medical equipment provider’s stock valued at $887,000 after purchasing an additional 129 shares during the period. Finally, Fulton Bank N.A. lifted its holdings in shares of Intuitive Surgical by 7.4% in the third quarter. Fulton Bank N.A. now owns 3,070 shares of the medical equipment provider’s stock worth $1,508,000 after buying an additional 211 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $578.55 on Tuesday. The firm’s 50-day moving average is $550.40 and its two-hundred day moving average is $510.02. The company has a market capitalization of $206.07 billion, a PE ratio of 90.26, a price-to-earnings-growth ratio of 5.51 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $364.17 and a 12 month high of $616.00.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $539.00, for a total value of $202,664.00. Following the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,967,734. This trade represents a 6.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jamie Samath sold 108 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total value of $58,542.48. Following the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at $4,746,819.42. This trade represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,843 shares of company stock worth $15,357,560. 0.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of recent research reports. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Bernstein Bank increased their target price on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Royal Bank of Canada lifted their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $522.00 to $650.00 in a research report on Monday, December 2nd. Finally, Piper Sandler restated an “overweight” rating and set a $670.00 price objective (up from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.